CURE sat down with Dr. Kerry A. Rogers for an interview at the Hairy Cell Leukemia Foundation 2025 Conference, hosted in Bologna, Italy. We sat down with Dr. Kerry A. Rogers for an interview at the ...
CURE attended the Hairy Cell Leukemia Foundation 2025 Conference where medical experts gathered to discuss advances in research and patient care. CURE had the privilege of attending the Hairy Cell ...
Hairy cell leukaemia (HCL) remains an intriguing B‐cell malignancy defined by its distinctive “hairy” cytoplasmic projections and its unique pattern of bone marrow infiltration. Recent research has ...
Patients with relapsed or refractory hairy cell leukemia who were treated with vemurafenib experienced excellent response and relapse-free survival, according to a recent clinical trial published in ...
Real-world treatment utilization patterns, discontinuation and healthcare resource utilization of first-line (1L) bruton tyrosine kinase inhibitor (BTKi) therapy in chronic lymphocytic leukemia (CLL): ...
Enormous progress in the treatment of hairy cell leukemia over the last five decades has emerged as a result of organized clinical investigations. Although interferon represented one of the initial ...
Patients with relapsed or refractory hairy cell leukemia who were treated with vemurafenib experienced excellent response and relapse-free survival, according to a recent clinical trial published in ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results